Executive Summary: International Pharmacy Purchasing: Canadian Pharmacies, the Legal Landscape, and the Savings
LFP-10.05 — The Cost Management Frontier#
The price differential between American and Canadian pharmacies for brand-name drugs is not a marginal variance. A 2024 RAND Corporation analysis found that US drug prices were 278 percent of prices in 33 OECD comparison countries. For brand-name originators, US prices averaged 422 percent of comparison country prices at manufacturer gross prices. Canadian drug prices specifically were 44 percent of US prices across all drugs and 31 percent of US prices for brand-name originators. A medication costing $1,000 per month in the US costs $310 to $440 in Canada. Generic semaglutide patent expiry occurred in Canada in January 2026, while US patent protection extends at least through 2033, creating a seven-year window in which Canadian patients have generic access that American patients do not. For a plan member paying $12,000 per year for branded semaglutide, Canadian generic alternatives at 70 to 80 percent below US brand pricing represent $8,000 to $10,000 in annual savings per member.
The legal structure appears prohibitive and is substantially more permissive in practice. The Federal Food, Drug, and Cosmetic Act technically prohibits importation of unapproved prescription drugs, but the FDA’s Personal Importation Policy exercises enforcement discretion for personal-use quantities under specific conditions. Seizure rates for personal-use orders from CIPA-certified Canadian pharmacies remain below 0.1 percent. The plan does not import drugs. Members import drugs for personal use, operating within the enforcement discretion zone that has applied for two decades.
The Canadian International Pharmacy Association provides the verification infrastructure. CIPA has maintained a 100 percent safety record across more than 10 million patients served since 2002. Only 51 pharmacy websites currently meet CIPA standards. Members provide a valid US prescription; the Canadian pharmacy verifies with the prescribing physician; medication ships via mail order in 90-day quantities.
For a 25-person plan with four members on high-cost brand-name maintenance medications, a conservative 40 percent reduction in Canadian pharmacy pricing produces $28,000 in annual savings against a baseline US spend of $70,000. At 60 percent, savings reach $42,000. Against a $375,000 expected claims fund, pharmacy savings alone represent 7 to 11 percent of total expected claims. Member acceptance is the most significant barrier; the plan cannot mandate international pharmacy use, only incentivize it. Supply reliability for high-demand GLP-1 medications is a genuine operational constraint requiring backup domestic access. For plans with significant brand-name drug exposure, the legal framework is more permissive than statutory text suggests and the operational infrastructure already exists through CIPA-certified pharmacies.